Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression

Cancer Science

Volumn 100, Issue 7, 2009, Pages 1317-1325

  Imai, Naoko ^a   Ikeda, Hiroaki ^a   Tawara, Isao ^a   Wang, Linan ^a   Wang, Lijie ^a   Nishikawa, Hiroyoshi ^a   Kato, Takuma ^a   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IMMUNOGLOBULIN G2A; INTERLEUKIN 2 RECEPTOR ALPHA; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER CONTROL; CANCER INFILTRATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; FEMALE; FIBROSARCOMA; IMMUNOSTIMULATION; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; TUMOR REJECTION; UPREGULATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; FEMALE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 67449092763     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01179.x     Document Type: Article

References (54)

1. + T lymphocytes in rhesus macaques. J Immunol Meth 2007; 325: 20-34.
2. H1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13: 843-50.
3. De Rosa SC, Lu FX, Yu J et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004; 173: 5372-80.
4. + T lymphocytes with cellular maturation. J Exp Med 2006; 203: 2865-77.
5. + T cells. Blood 2006; 107: 4781-9.
6. + T cell responses. J Exp Med 2007; 204: 1405-16.
7. + memory T lymphocyte populations. Eur J Immunol 2007; 37: 3089-100.
8. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204: 2473-85.
9. Duvall MG, Precopio ML, Ambrozak DA et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 2008; 38: 350-63.
10. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: Unravelling the immune system. Nat Rev Immunol 2004; 4: 648-55.
11. + T cells. Eur J Immunol 2009; 39: 241-53.
12. Ikeda H, Ohta N, Furukawa K et al. Mutated mitogen-activated protein kinase: A tumor rejection antigen of mouse sarcoma. Proc Natl Acad Sci USA 1997; 94: 6375-9.
13. + T cell adoptive immunotherapy. Immunity 2000; 13: 265-76.
14. Nocentini G, Giunchi L, Ronchetti S et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci USA 1997; 94: 6216-21.
15. + regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3: 135-42.
16. + immunoregulatory T cells: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16: 311-23.
17. + T cells. J Immunol 2004; 172: 7306-14.
18. Tone M, Tone Y, Adams E et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci USA 2003; 100: 15 059-64.
19. + T cell activation and experimental autoimmune encephalomyelitis. J Immunol 2004; 172: 4686-90.
20. Ronchetti S, Zollo O, Bruscoli S et al. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 2004; 34: 613-22.
21. + T cells. J Immunol 2004; 173: 5008-20.
22. + T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res 2008; 68: 5948-54.
23. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200: 771-82.
24. + regulatory T cells. J Exp Med 2005; 202: 885-91.
25. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 2006; 176: 6434-42.
26. + T-cell responses and tumor immunity. Cancer Res 2006; 66: 4904-12.
27. Calmels B, Paul S, Futin N, Ledoux C, Stoeckel F, Acres B. Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. Cancer Gene Ther 2005; 12: 198-205.
28. + T cell dependent anti-tumor immunity. Cancer Immunol Immunother 2008. doi 10.1007/s00262-008-0622-2.
29. Van Pel A, De Plaen E, Boon T. Selection of highly transfectable variant from mouse mastocytoma P815. Somat Cell Mol Genet 1985; 11: 467-75.
30. Nagata Y, Furugen R, Hiasa A et al. Peptides derived from a wild-type murine proto-oncogene c-erb B-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159: 1336-43.
31. Yuan J, Gnjatic S, Li H et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 2008; 105: 20 410-15.
32. Staveley-O'Carroll K, Sotomayor E, Montgomery J et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95: 1178-83.
33. + regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
34. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002; 3: 999-1005.
35. Ganss R, Arnold B, Hammerling GJ. Mini-review: Overcoming tumor-intrinsic resistance to immune effector function. Eur J Immunol 2004; 34: 2635-41.
36. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-60.
37. Blattman JN, Greenberg PD. Cancer immunotherapy: A treatment for the masses. Science 2004; 305: 200-5.
38. Pure E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nat Immunol 2005; 6: 1207-10.
39. Bronte V, Zanovello P. Regulation of immune responses by 1-arginine metabolism. Nat Rev Immunol 2005; 5: 641-54.
40. Sitkovsky M, Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors. Nat Rev Immunol 2005; 5: 712-21.
41. Hamzah J, Jugold M, Kiessling F et al. Vascular normalization in Rgs 5-deficient tumours promotes immune destruction. Nature 2008; 453: 410-14.
42. Buckanovich RJ, Facciabene A, Kim S et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008; 14: 28-36.
43. Willimsky G, Czeh M, Loddenkemper C et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 2008; 205: 1687-700.
44. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res 1999; 59: 3128-33.
45. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2: 816-22.
46. + regulatory T cells during the course of transplantable tumor growth and protection from 3-methylcholanthrene-induced tumorigenesis by CD25-depletion. Jpn J Cancer Res 2002; 93: 911-16.
47. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-62.
48. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
49. + T cells blocks their inhibitory activity: A novel regulatory role for OX40 and its comparison with GITR. Blood 2005; 105: 2845-51.
50. Shevach EM, Stephens GL. The GITR-GITRL interaction: Co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol 2006; 6: 613-18.
51. + T cells by bacterial vector. Blood 2008; 111: 1404-12.
52. + effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol 2007; 179: 7365-75.
53. Baltz KM, Krusch M, Bringmann A et al. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/ tumor cell interactions. FASEB J 2007; 10: 2442-54.
54. Baessler T, Krusch M, Schmiedel BJ et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res 2009; 69: 1037-45.